Researchers involved in an international study have reported that a new tyrosine kinase inhibitor, bosutinib, appears to be superior to […]
A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially […]
People with chronic myeloid leukemia (CML) that is in complete remission after two years of treatment with Gleevec® (imatinib) have […]
According to updated results from a Phase III clinical trial, Tasigna® (nilotinib) continues to be more effective than Gleevec® (imatinib) […]
The U.S. Food and Drug Administration has expanded the approval of Sprycel® (dasatinib) to include the initial treatment of patients […]
The U.S. Food and Drug Administration has expanded the approval of Tasigna® (nilotinib) to include the initial treatment of patients […]
In the initial treatment of chronic myeloid leukemia (CML), Sprycel® (dasatinib) produces higher response rates than Gleevec® (imatinib). These results […]
Survivors of non-central nervous system (CNS) childhood cancers reported a statistically and clinically significantly higher rate of neurocognitive impairment than […]
Study Evaluates Long-term Efficacy of Peripheral Blood Stem Cell Transplant Versus Bone Marrow Transplant
For leukemia patients who undergo allogeneic stem cell transplantation, 10-year results indicate that bone-marrow transplantation (BMT) and peripheral blood stem […]
Tasigna May Be More Effective than Gleevec for Initial Treatment of CML
As the month of September brings leukemia and lymphoma into focus, it’s time to increase public understanding of these diseases, including their prevalence, approaches to screening and prevention, treatment options, and resources that offer updated leukemia and lymphoma information throughout the year.
Sprycel® (dasatinib) produces a higher response rate and improves progression-free survival in patients with chronic myeloid leukemia (CML) who have grown resistant to Gleevec® (imatinib), according to the results of a study published early online in Cancer.
Industrial workers who are exposed to formaldehyde may be at an increased risk of dying from blood and lymphatic cancers, particularly myeloid leukemia but also Hodgkin’s lymphoma and multiple myeloma, according to the results of a study published in the Journal of the National Cancer Institute.
Down-to-earth and down-to-business when it comes to cancer advocacy, Erin Zammett Ruddy discusses her very public journey with chronic myeloid […]
The American Society of Clinical Oncology 2008: Highlights of Treatment of Hematological Malignancies
The American Society of Clinical Oncology 2008: Highlights of Treatment of Hematological Malignancies The 2008 annual meeting of the American […]
Early Dose Intensity of Gleevec® May Optimize Response for Chronic Phase CML Patients with newly diagnosed chronic phase chronic myeloid […]
LYN Kinase Affects Sensitivity to Gleevec® in Chronic Myeloid Leukemia A protein structure known as the LYN kinase appears to play an important role in the effectiveness of Gleevec® (imatinib mesylate) in chronic myeloid leukemia (CML) cancer cells. These results were recently published in the Journal of the National Cancer Institute . Chronic myeloid leukemia is a cancer that originates in the immune cells.
Sprycel® Effective for Newly Diagnosed Chronic Myeloid Leukemia The targeted agent Sprycel® (dasatinib) is an effective treatment for patients newly […]